Context Therapeutics (CNTX) Cash from Operations (2020 - 2026)
Context Therapeutics (CNTX) posted Cash from Operations of 11429374.0 for Q1 2026, down 27.8% sequentially from 8942955.0 in Q4 2025, and down 127.3% YoY from 41869987.34 in Q1 2025.
Context Therapeutics (CNTX) Cash from Operations (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 11429374.0 in Q1 2026.
- Quarterly Cash from Operations fell 127.3% year-over-year to 11429374.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32786373.0 (down 115.36% YoY) and the FY2025 annual result came in at 26385380.0, down 81.26% from the prior year.
- Cash from Operations declined to 11429374.0 in Q1 2026 per CNTX's latest filing, from 8942955.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1933328.0 in Q3 2024 and troughed at 11429374.0 in Q1 2026.
- A 5-year average of 5115767.06 and a median of 4631107.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations sank 6762.0% in 2022, then soared 44.14% in 2024.
- Over 5 years, Cash from Operations stood at 3929673.0 in 2022, then sank by 83.91% to 7227172.0 in 2023, then soared by 32.11% to 4906732.0 in 2024, then plunged by 82.26% to 8942955.0 in 2025, then decreased by 27.8% to 11429374.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 11429374.0, 8942955.0, and 6578864.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | -7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.02 Mn |
| Jun 30, 2026 | -7.02 Mn |
| Mar 31, 2026 | -11.43 Mn |
| Mar 31, 2026 | -11.43 Mn |
| Dec 31, 2025 | -8.94 Mn |
| Dec 31, 2025 | -8.94 Mn |
| Sep 30, 2025 | -6.58 Mn |
| Sep 30, 2025 | -6.58 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Dec 31, 2024 | -4.91 Mn |
| Dec 31, 2024 | -4.91 Mn |
| Sep 30, 2024 | -1.93 Mn |
| Sep 30, 2024 | -1.93 Mn |
| Jun 30, 2024 | -3.36 Mn |
| Jun 30, 2024 | -3.36 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Mar 31, 2024 | -4.36 Mn |